Increased intestinal absorption in the era of teduglutide and its impact on management strategies in patients with short bowel syndrome-associated intestinal failure.
Short bowel syndrome-associated intestinal failure (SBS-IF) as a consequence of extensive surgical resection of the gastrointestinal (GI) tract results in a chronic reduction in intestinal absorption. The ensuing malabsorption of a conventional diet with associated diarrhea and weight loss results in a dependency on parenteral nutrition and/or intravenous fluids (PN/IV). A natural compensatory process of intestinal adaptation occurs in the years after bowel resection as the body responds to a lack of sufficient functional nutrient-processing intestinal surface area. The adaptive process improves bowel function but is a highly variable process, yielding different levels of symptom control and PN/IV independence among patients. Intestinal rehabilitation is the strategy of maximizing the absorptive capacity of the remnant GI tract. The approaches for achieving this goal have been limited to dietary intervention, antidiarrheal and antisecretory medications, and surgical bowel reconstruction. A targeted pharmacotherapy has now been developed that improves intestinal absorption. Teduglutide is a human recombinant analogue of glucagon-like peptide 2 that promotes the expansion of the intestinal surface area and increases the intestinal absorptive capacity. Enhanced absorption has been shown in clinical trials by a reduction in PN/IV requirements in patients with SBS-IF. This article details the clinical considerations and best-practice recommendations for intestinal rehabilitation, including optimization of fluids, electrolytes, and nutrients; the integration of teduglutide therapy; and approaches to PN/IV weaning.
Vanderbilt Center for Human Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Douglas L
DL
Seidner
Lauren K
LK
Schwartz
Marion F
MF
Winkler
Khursheed
K
Jeejeebhoy
Joseph I
JI
Boullata
Kelly A
KA
Tappenden
D000222:Adaptation, Physiological / Q000187:drug effects*; D013505:Digestive System Surgical Procedures / Q000009:adverse effects; D005765:Gastrointestinal Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D007410:Intestinal Diseases / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000534:rehabilitation; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000378:metabolism; D044342:Malnutrition / Q000378:metabolism / Q000517:prevention & control*; D018529:Nutritional Support; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy* / Q000503:physiopathology; D012778:Short Bowel Syndrome / Q000150:complications* / Q000601:surgery
D005765:Gastrointestinal Agents; D010455:Peptides; C494910:teduglutide